Qilu Pharmaceutical Leads with 59 Approved Generics as Anti-infective Market Shrinks by Over RMB 50 Billion; 16 Products Set for 11th National Volume-based Procurement
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Since 1928PenicillinSince their inception, humanity has achieved milestone breakthroughs in the field of anti-infective drug development, creating various types of anti-infective drugs, including antibacterial agents represented by antibiotics, antifungal agents, antiviral agents, anti-mycobacterial agents, as well as vaccines, immune sera, and immunoglobulins among other biological products. These drugs play an irreplaceable role in clinical practice, saving the lives of countless patients.
"Shrinking" by over 50 billion! Anti-infective drugs lose their former glory, Qilu Pharmaceutical leads the list of approvals.
According to the database of Mose Pharmaceuticals, as of May 16, 263 anti-infective drugs have been approved or are considered to have passed the generic drug consistency evaluation by enterprises. In terms of the number of varieties that have passed the evaluation, 79 varieties have been approved by 10 or more enterprises.Amoxicillin CapsulesLed by 51 enterprises, andOseltamivir Phosphate Capsules(49 companies), LeftOfloxacin Tablets(41 companies)、Moxifloxacin Hydrochloride Eye Drops(41 companies)、Oseltamivir Phosphate for Suspension(40 institutions)、Tenofovir Alafenamide Fumarate Tablets(39 companies)、Sodium Cefuroxime for Injection(38 companies)Following closely.
Before 2019, the market for anti-infective drugs in China showed a growth trend. Data from Moxie Pharmaceutical shows that systemic anti-infective drugs(Chemical Medicine)Sales Peak in China's Hospital Terminal Market Exceeds 209 Billion Yuan. After 2020, the market size significantly dropped due to national policies to curb antibiotic overuse, improved hygiene and vaccination efforts, implementation of COVID-19 control measures, and price reductions for some drugs from centralized procurement. However, with the waning of the pandemic's impact, the market has shown a gradual recovery trend. In 2023, the hospital market size reached 147.9 billion yuan, reflecting a "shrinkage" of over 50 billion yuan compared to 2019.
Source of the image: Mosun Medicine National Hospital Sales (All-Terminal) Database
Top 10 Systemic Anti-Infective Chemical Drugs: Pfizer, Fosun, and Guangzhou Pharma Lead the Market
In the terminal market of hospitals across China, among the TOP50 products of systemic anti-infective chemical drugs, 22 products have annual sales exceeding 2 billion yuan, whereinCefoperazone Sulbactam、Piperacillin Tazobactam、Amoxicillin Clavulanate Potassium(By generic name)Ranking in the top three, the hospital sales in 2023 exceeded 9.5 billion yuan, 8.1 billion yuan, and 5.2 billion yuan respectively.
Among the TOP30 products of systemic anti-infective chemical drugs,PfizerFive drugs made the list,Cefoperazone Sodium and Sulbactam Sodium for Injection（2:1）、Nirmatrelvir Tablets/Ritonavir TabletsCombination Packaging,Ceftazidime Avibactam Sodium for Injection（4:1）Sales growth rates all exceeded 20%; among themCefoperazone Sodium and Sulbactam Sodium for Injection（2:1）Stably Ranking First, Hospital Terminal Market Sales Reached Nearly 7 Billion Yuan in 2023.
Screenshot source: Mosentropy Medicine National Hospital Sales (All-Terminal) Database
Countdown to the 11th National Drug Procurement in China! 16 Popular Varieties Prepare for Action
As a leading category in clinical drug expenditure, anti-infective drugs have always been a key focus of China's national drug procurement. Currently, 84 systemic anti-infective drug varieties have been included in the national procurement, along with 16 other popular varieties.(such as Cefoxitin Sodium for Injection, Levofloxacin Injection, etc.)The procurement condition of having ≥7 qualified enterprises has been met, involving 130 enterprises.Bait、Qilu、Zhengda Tianqing、Yangtze RiverMultiple products from companies such as Qilu Pharmaceutical are included in the list, and the eleventh batch of centralized procurement may further reshape the market competition landscape.
Source of the image: Mosentropy Medicine Evaluation Drug Summary Database
It is worth mentioning that, as of now, 34 pharmaceutical companies haveSodium Cefozopran for InjectionPassed or deemed to have passed, involvingShanghai Pharmaceutical、Luoxin Pharmaceutical、Jichuan Pharmaceutical、China Resources Pharmaceutical、Sinopharm Group、Bait Pharmaceutical、Qilu PharmaceuticalSuch as 34 enterprises. In addition, there are 25 enterprises whose products have submitted supplementary applications for consistency evaluation or are under review for production registration in a new category, involvingShandong Lukang Pharmaceutical、Zhejiang Yongning Pharmaceutical、Guangdong Jincheng Jinsu Pharmaceutical、Haikou Pharmaceutical、Wuhan Hengtai Pharmaceuticaletc.
END
This article is original. Please leave a message to obtain authorization for reprint.
More RecentlyMoxie ConsultingPopular report, scan the QR code below to claim
Contact us to experience more professional services from Mosen Pharma. | ||||
MeetingDiscussion CombinedMade | GardenDistrict TakeWu | Database Consultation | Customization Service | Media Cooperation |
ClickImage Above, you can start the Mosan Chemistry data query